Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Do Kim has maintained an Overweight rating on Ionis Pharmaceuticals (NASDAQ:IONS) and increased the price target from $60 to $62, indicating a positive outlook on the company's stock.
January 18, 2024 | 5:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals' stock rating remains Overweight by Piper Sandler, with a raised price target from $60 to $62, suggesting confidence in the company's future performance.
The increase in price target by Piper Sandler is a positive signal to investors, often leading to a bullish sentiment in the short term. As the rating is maintained at Overweight and the target is raised, it reflects an expectation of continued performance and potential upside for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100